Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis Patients Mar 26
AnGes, Inc., Annual General Meeting, Mar 27, 2026 Feb 10
AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026 Dec 03
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients Sep 04
AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025 Sep 01
AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025 May 31
AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025 Mar 01
AnGes, Inc., Annual General Meeting, Mar 28, 2025 Feb 14
AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025 Dec 03
Third quarter 2024 earnings released: JP¥15.06 loss per share (vs JP¥0.17 profit in 3Q 2023) Nov 10
AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Aug 27
Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023) Aug 14
AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jun 02
First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023) May 13
AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024 Mar 23
AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe Mar 20
AnGes, Inc., Annual General Meeting, Mar 28, 2024 Feb 11
Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022) Feb 11
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan Jan 19
AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024 Dec 05
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study Nov 15
Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022) Nov 09
New major risk - Share price stability Oct 20
Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022) Aug 10
AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd. Jul 13
AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding Jun 27
AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023 May 28
First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022) May 12
AnGes, Inc., Annual General Meeting, Mar 30, 2023 Feb 12
Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021) Feb 12
AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023 Dec 28
Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021) Nov 17
No independent directors Nov 16
Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021) Nov 10
AnGes, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Aug 28
Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021) Aug 11
AnGes, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jun 29
First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021) May 11
No independent directors Apr 27
AnGes, Inc. to Report Q1, 2022 Results on May 10, 2022 Feb 27
AnGes, Inc., Annual General Meeting, Mar 30, 2022 Feb 16
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 11
Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020) Nov 06
Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020) Aug 08
First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020) May 11
AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm Mar 25
AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm Mar 09
New 90-day low: €8.90 Feb 20
Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019) Feb 18
AnGes, Inc., Annual General Meeting, Mar 30, 2021 Feb 17
AnGes, Inc. to Report Fiscal Year 2020 Results on Feb 15, 2021 Dec 30
AnGes, Inc. (TSE:4563) completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others. Dec 17
Third quarter 2020 earnings released: JP¥10.39 loss per share Nov 15
Third quarter earnings released Oct 26
AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey Oct 16
New 90-day low: €10.50 Oct 14
AnGes, Inc. to Report Q3, 2020 Results on Oct 26, 2020 Aug 30